Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results


1.		A Study Comparing the Combination of Doxil and Yondelis, to Doxil Alone for Subjects With Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ET743-OVA-301 ET743-OVA-301, NCT00113607

Last Modified: 10/7/2005 First Published: 8/1/1999


2.		Phase II Study of Ecteinascidin 743 in Patients With Advanced Soft Tissue Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								EORTC-62982 NCT00003939

Last Modified: 8/1/2001 First Published: 5/1/2000


3.		Phase II Study of Ecteinascidin 743 in Patients With Previously Treated Metastatic Osteosarcoma (Summary Last Modified 08/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				12 and over				NCI, Pharmaceutical / Industry				MSKCC-99098 PMAR-ET-019-99, NCI-G00-1761, NCT00005625

Last Modified: 1/1/2002 First Published: 6/1/2001


4.		Phase II Study of Ecteinascidin 743 in Patients With Previously Treated, Unresectable Advanced or Metastatic Soft Tissue Sarcoma (Summary Last Modified 01/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-01018 PMAR-ET-B-022-00, NCI-G01-1948, NCT00017030

Last Modified: 6/1/2002 First Published: 12/1/2001


5.		Phase II Study of Ecteinascidin 743 in Patients With Unresectable Malignant Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-01084 PMAR-ET-B-020-99, NCI-G01-2026, NCT00027508


6.		A Study of ET743 in Subjects With Advanced Liposarcoma or Leiomyosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ET743-STS-201 ET743-STS-201, NCT00060944


7.		Phase 2 Study of ET-743 in Subjects With Advanced Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ET743-INT-11 NCT00050414


8.		ET-743 in Subjects With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ET743-INT-3 NCT00050427


9.		Phase 2 Study of ET-743 in Persistent or Recurrent Endometrial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ET743-USA-1 NCT00050440

Last Modified: 11/5/2008 First Published: 9/15/2006


10.		Phase II Study of Trabectedin in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 and over				NCI				GOG-0087M NCT00379145

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute